Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network will create an ethnically diverse single-cell atlas of the response to commonly used vaccines such as flu vaccines with a focus on responses in lymph nodes.

© Shutterstock/Numstocker

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells.

In partnership with Imperial College London and the Uganda Virus Research Institute, the Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network aims to understand and ultimately to predict how humans respond to vaccination at a single-cell level, whilst simultaneously creating universally available on-line materials as resources for further research.

Prof Hashem Koohy, a Co-PI of the project and an Associate Professor of systems immunology at the MRC Human Immunology Unit said: ‘The LEGACY Network project is a very exciting multi institutional and multidisciplinary effort that aims to provide deeper insights into vaccine-induced differential immune response at single cell level in an ethnically diverse population.

‘The existing single cell data that build our prior knowledge of human diseases are mainly biased by European ancestry. The LEGACY Network provides an opportunity to study differential immune response to vaccines in the light of diversity and ancestry.’

Such projects have the potential to significantly advance understandings of how vaccines stimulate immunity across ethnicities and provide new insights for future efforts in vaccine design.

The resources created by the LEGACY Network will serve as a foundation for overcoming differences in vaccine efficacy associated with ancestry, and for accelerating and promoting equity in vaccine research.

Read the full news item on the University of Oxford’s website.

Recent stories

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Professor Marella de Bruijn receives MRC Programme Award

Congratulations to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.

Professor Bethan Psaila wins ISEH Janet Rowley Award

Congratulations to Professor Psaila, who has received the 2026 Janet Rowley Award from the International Society for Experimental Hematology, in recognition of her outstanding contributions in the field of experimental haematology.

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.